Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Is Schering Cutting Now?

It never ceases to amaze me how companies can announce such large cost-cutting measures when things are looking bleak for their revenue growth. Why was it OK for them to have all that extra fat in the first place?

The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough (NYSE: SGP  ) . Granted, some of the cuts are necessary now that doctors aren't interested in hearing Schering's sales reps push its cholesterol drugs. But only some of $1 billion in new savings that Schering hopes to achieve -- on top of an additional $500 million announced previously -- has to do directly with its joint partnership with Merck (NYSE: MRK  ) to sell Zetia and Vytorin. Why had Schering amassed so many superfluous upper-level managers in the first place?

The cuts will come early and often, with most completed by the end of 2010. Including the synergies associated with its acquisition of Akzo Nobel's (Nasdaq: AKZOY  ) Organon BioSciences subsidiary, Schering aims to cut its staff by 10%. In total, the reduced costs could give a 10% boost to the bottom line at a time when the company will likely have trouble growing sales.

Most of the cuts will come in the U.S., since sales of Schering's international drug offerings are actually doing quite well. It recently updated its deal with Johnson & Johnson (NYSE: JNJ  ) to sell J&J's anti-inflammatory Remicade outside the U.S. Moreover, management says that its international cholesterol drug sales aren't being hurt, because the Enhance trial isn't getting as much press in other countries. Any international growth is a welcome sign for Schering, especially if the dollar falls further.

In this market, cost-cutting is the new black -- Wyeth (NYSE: WYE  ) did it just last week. This Fool just wants to know what took the companies so long to slim down.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 614541, ~/Articles/ArticleHandler.aspx, 10/26/2016 11:32:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,219.81 50.54 0.28%
S&P 500 2,143.51 0.35 0.02%
NASD 5,278.83 -4.57 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/3/2009 4:02 PM
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****
JNJ $115.06 Up +1.10 +0.97%
Johnson and Johnso… CAPS Rating: ****
MRK $61.36 Down -0.60 -0.96%
Merck and Co. CAPS Rating: ****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***